Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis | MicrobiomeTrials← Back to trialsNCT04688788
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2021-04-28Est. Completion: 2026-06-10
Enrollment target: 600 participants Locations- Danish Multiple Sclerosis Center, Rigshospitalet, Glostrup Municipality, Copenhagen, Denmark
- Department of Neurology, Aalborg University Hospital, Aalborg, Denmark
- Department of Neurology, Aarhus University Hospital, Aarhus, Denmark
- Department of Neurology, Hospital of South West Jutland, Esbjerg, Esbjerg, Denmark
- Department of Neurology, Herlev Hospital, Herlev, Denmark
- Department of Neurology, Nordsjællands Hospital i Hillerød, Hillerød, Denmark
- Department of Neurology, Regionshospitalet Holstebro, Holstebro, Denmark
- Department of Neurology, Kolding Hospital, Kolding, Denmark
- Department of Neurology, Odense University Hospital, Odense, Denmark
- Department of Neurology, Hospital of Southern Jutland, Sønderborg, Sønderborg, Denmark
- Department of neurology, Regionshospitalet Viborg, Viborg, Denmark
Other microbiome trials you might be interested in
Multiple SclerosisTomography, Optical CoherenceRetinal DegenerationVisual Acuity
This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in …
Baltimore, United StatesCompleted Mar 2027
Multiple Sclerosis, Relapsing-Remitting
Rationale: B-cell depleting therapies like ocrelizumab are very effective in the treatment of relapsing remitting multip…
Amsterdam, NetherlandsEst. completion Feb 2027